FY2026 EPS Estimates for HUTCHMED Increased by Trinity Delta

HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) – Research analysts at Trinity Delta boosted their FY2026 earnings per share (EPS) estimates for HUTCHMED in a report issued on Tuesday, June 9th. Trinity Delta analyst L. Gregorek now anticipates that the company will post earnings per share of $0.30 for the year, up from their previous estimate of $0.25. The consensus estimate for HUTCHMED’s current full-year earnings is $0.47 per share.

Several other equities analysts have also commented on the company. Weiss Ratings lowered HUTCHMED from a “hold (c)” rating to a “hold (c-)” rating in a research report on Friday, May 1st. Morgan Stanley set a $13.60 target price on HUTCHMED in a research report on Thursday, May 28th. Bank of America decreased their target price on HUTCHMED from $21.00 to $20.00 and set a “buy” rating for the company in a research report on Tuesday, March 10th. Finally, Wall Street Zen downgraded HUTCHMED from a “buy” rating to a “hold” rating in a research note on Saturday, March 7th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, HUTCHMED currently has an average rating of “Hold” and an average target price of $16.80.

HUTCHMED Stock Performance

Shares of HUTCHMED stock opened at $10.71 on Friday. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.96 and a quick ratio of 4.83. The business has a fifty day simple moving average of $13.20 and a two-hundred day simple moving average of $13.95. HUTCHMED has a 12 month low of $10.40 and a 12 month high of $19.50.

Institutional Investors Weigh In On HUTCHMED

A number of institutional investors have recently added to or reduced their stakes in HCM. Jane Street Group LLC grew its holdings in HUTCHMED by 128.0% during the 1st quarter. Jane Street Group LLC now owns 222,241 shares of the company’s stock valued at $3,343,000 after buying an additional 124,771 shares in the last quarter. UBS Group AG lifted its position in HUTCHMED by 112.8% in the third quarter. UBS Group AG now owns 137,000 shares of the company’s stock worth $2,158,000 after buying an additional 72,614 shares during the last quarter. Amundi lifted its position in HUTCHMED by 41.9% in the third quarter. Amundi now owns 223,330 shares of the company’s stock worth $3,620,000 after buying an additional 65,898 shares during the last quarter. M&G PLC increased its stake in HUTCHMED by 26.7% in the fourth quarter. M&G PLC now owns 259,033 shares of the company’s stock worth $3,367,000 after purchasing an additional 54,601 shares during the period. Finally, XY Capital Ltd increased its stake in HUTCHMED by 291.1% in the third quarter. XY Capital Ltd now owns 52,757 shares of the company’s stock worth $831,000 after purchasing an additional 39,266 shares during the period. 8.82% of the stock is owned by hedge funds and other institutional investors.

HUTCHMED Company Profile

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.